ReviewFrontiers in medicine2025
Red blood cell extracellular vesicles: new frontiers in hematological biomarker discovery.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Single-Cell Immune Atlases to Map Small Extracellular Vesicle Cargo in Tuberculosis-Diabetes Comorbidity: A Narrative Review and Conceptual Roadmap.International journal of molecular sciences · 2026Review
- Small RNAs, big impact: microRNAs in malaria pathogenesis, therapeutic opportunities, and challenges.Frontiers in cellular and infection microbiology · 2026Review
- Red Blood Cell-Derived Extracellular Vesicles for Gene and RNA Therapeutics: Biological, Engineering, and Translational Challenges.International journal of nanomedicine · 2026Review
- Molecular Mechanisms of Transfusion-Associated Immunomodulation and Its Impact in the Critically Ill.International journal of molecular sciences · 2025Review
- Nanocarrier-Based Delivery Systems for Natural Compounds Across Research Stages.Materials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) offer promising opportunities in hematology for improved diagnostics, prognostics, and therapeutics, making them valuable tools in the molecular landscape. EVs derived from red blood cells (RBCs) are the primary source of EVs in the bloodstream. They perform several critical biological and physiological functions, such as facilitating intercellular communication and transferring biomolecules like DNA, RNA, and proteins. Hence, in this review, we aim to explore RBC-derived EVs and their potential as a diagnostic tool for their clinical relevance and associated biomarkers in hematology. Furthermore, we emphasized their crucial role in both physiology and disease. RBC-EVs are found to play a role in vascular damage, inflammation, and coagulopathy in several pathophysiological conditions, potentially influencing the progression of certain diseases. They also served as indicators for numerous conditions, including hereditary hematologic abnormalities, diabetes, and cardiovascular diseases. Hence, their importance lies in their ability to reflect and influence red cell health, immune responses, and systemic disease states as accessible, non-invasive indicators. Also, their composition mirrors the physiological or pathological state of RBCs and holds promise for both diagnostics and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.